


# Deucravacitinib

The safety and efficacy of deucravacitinib, an investigational agent, have not been established.

## About the TYK2 Immune Pathway

Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates select immune and inflammatory pathways.<sup>1-7</sup>



## About Deucravacitinib



Deucravacitinib is a first-in-class, oral, selective TYK2 inhibitor with a unique mechanism of action.



Deucravacitinib was designed to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in the pathogenesis of immune-mediated diseases.

## What Sets Deucravacitinib Apart



At therapeutic doses, deucravacitinib has not been shown to inhibit pathways that are mediated only by JAK1, 2, 3, including those involved in hematopoiesis, myelopoiesis and lipid metabolism.



Deucravacitinib has the potential to become an important treatment option for patients who require systemic therapy for their moderate to severe plaque psoriasis, with the convenience of a once-daily oral dose.

## Deucravacitinib Clinical Trials

Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases.<sup>8-14</sup>

Disease Area	Phase 2	Phase 3
Psoriatic arthritis <small>Phase 2 psoriatic arthritis data shared during American College of Rheumatology 2020 meeting.</small>	✓	
Crohn's disease	✓	
Ulcerative colitis	✓	
Lupus	✓	
Psoriasis		✓

Deucravacitinib is an investigational treatment option and is not approved for use by a regulatory authority in any country.

**Bristol Myers Squibb is committed to pursuing pathbreaking science to deliver meaningful solutions that address unmet needs and improve the lives of people living with psoriasis and other immune-mediated diseases.**

1. Min X., et al. J Biol Chem 2015;290:27261-27270.  
 2. Jani M., et al. Ann Rheum Dis 2014;73:1750-1752.  
 3. Smith J.A., Colbert RA. Arthritis Rheumatol 2014;66:231-241.  
 4. Hofer M.J., Campbell IL. Cytokine Growth Factor Rev 2013;24:257-267.  
 5. Paniagua R.T., et al. J Am Acad Dermatol 2011;65:389-403.  
 6. O'Sullivan L.A., et al. Mol Immunol 2007;44:2497-2506.  
 7. Burke J.R., et al. Sci Transl Med 2019;11:eaaw1736.  
 8. Bristol Myers Squibb. Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA). <https://clinicaltrials.gov/ct2/show/NCT03881059>. NLM identifier: NCT03881059.  
 9. Bristol Myers Squibb. Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus. <https://clinicaltrials.gov/ct2/show/NCT03920267>. NLM identifier: NCT03920267.  
 10. Bristol Myers Squibb. An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus. <https://clinicaltrials.gov/ct2/show/NCT03252587>. NLM identifier: NCT03252587.  
 11. Bristol Myers Squibb. An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis. <https://www.clinicaltrials.gov/ct2/show/NCT03943147>. NLM identifier: NCT03943147.  
 12. Bristol Myers Squibb. Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC). <https://clinicaltrials.gov/ct2/show/NCT03934216>. NLM identifier: NCT03934216.  
 13. Bristol Myers Squibb. An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease. <https://clinicaltrials.gov/ct2/show/NCT03599622>. NLM identifier: NCT03599622.  
 14. Bristol Myers Squibb. Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis. <https://clinicaltrials.gov/ct2/show/NCT03624127>. NLM identifier: NCT03624127.